Clinical trial
Use of ACA 125 in Patients With Ovarian Cancer: Safety and Immune Response
NCT00103545 · AGO Study Group, Other · Completed
Key facts
| NCT number | NCT00103545 |
|---|---|
| Title | Use of ACA 125 in Patients With Ovarian Cancer: Safety and Immune Response |
| Official title | A Phase I/II Trial of ACA 125 in Patients With Recurrent Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer |
| Lead sponsor | AGO Study Group, Other |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Ovarian Cancer, Fallopian Tube Neoplasms, Peritoneal Neoplasms |
| Intervention type | Biological |
| Interventions | ACA 125 |
| Enrollment | 36 |
| Start date | Jul 1, 2003 |
| Completion | Aug 1, 2004 |
| First posted | Feb 11, 2005 |
| Last update posted | Oct 2, 2006 |
| Countries | Germany |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: